PMC:7523471 / 8010-9422 JSONTXT

{"project":"TEST0","denotations":[{"id":"33041751-231-239-816265","span":{"begin":309,"end":313},"obj":"[\"17420404\"]"},{"id":"33041751-230-238-816266","span":{"begin":333,"end":337},"obj":"[\"29213438\"]"},{"id":"33041751-227-235-816267","span":{"begin":352,"end":356},"obj":"[\"30014145\"]"},{"id":"33041751-235-243-816268","span":{"begin":373,"end":377},"obj":"[\"30131755\"]"},{"id":"33041751-228-236-816269","span":{"begin":401,"end":405},"obj":"[\"30203712\"]"},{"id":"33041751-230-238-816270","span":{"begin":423,"end":427},"obj":"[\"31520513\"]"},{"id":"33041751-235-243-816271","span":{"begin":443,"end":447},"obj":"[\"31261683\"]"},{"id":"33041751-145-153-816272","span":{"begin":595,"end":599},"obj":"[\"22474610\"]"},{"id":"33041751-167-175-816273","span":{"begin":874,"end":878},"obj":"[\"19829371\"]"},{"id":"33041751-187-195-816274","span":{"begin":894,"end":898},"obj":"[\"21603239\"]"},{"id":"33041751-214-222-816275","span":{"begin":921,"end":925},"obj":"[\"22562439\"]"},{"id":"33041751-232-240-816276","span":{"begin":948,"end":952},"obj":"[\"22474610\"]"},{"id":"33041751-232-240-816277","span":{"begin":970,"end":974},"obj":"[\"22343730\"]"},{"id":"33041751-230-238-816278","span":{"begin":991,"end":995},"obj":"[\"23026364\"]"},{"id":"33041751-229-237-816279","span":{"begin":1016,"end":1020},"obj":"[\"24614494\"]"},{"id":"33041751-233-241-816280","span":{"begin":1036,"end":1040},"obj":"[\"25806018\"]"},{"id":"33041751-234-242-816281","span":{"begin":1058,"end":1062},"obj":"[\"25904081\"]"},{"id":"33041751-234-242-816282","span":{"begin":1077,"end":1081},"obj":"[\"27645291\"]"},{"id":"33041751-234-242-816283","span":{"begin":1100,"end":1104},"obj":"[\"26440450\"]"},{"id":"33041751-234-242-816284","span":{"begin":1122,"end":1126},"obj":"[\"27026271\"]"},{"id":"33041751-231-239-816285","span":{"begin":1144,"end":1148},"obj":"[\"29312125\"]"},{"id":"33041751-230-238-816286","span":{"begin":1165,"end":1169},"obj":"[\"29562524\"]"},{"id":"33041751-234-242-816287","span":{"begin":1188,"end":1192},"obj":"[\"32066283\"]"},{"id":"33041751-167-175-816288","span":{"begin":1362,"end":1366},"obj":"[\"17698496\"]"},{"id":"33041751-184-192-816289","span":{"begin":1379,"end":1383},"obj":"[\"17401090\"]"},{"id":"33041751-211-219-816290","span":{"begin":1406,"end":1410},"obj":"[\"22474610\"]"}],"text":"Indeed, in recent years there has been tremendous progress in the development of AD diagnostic imaging biomarkers, including FDA-approved brain amyloid imaging via positron emission tomography (PET), as well as tau, surrogate markers of inflammation such as TSPO, and synaptic PET imaging (Rabinovici et al., 2007; Schilling et al., 2016; Chen et al., 2018; Edison et al., 2018; Narayanaswami et al., 2018; Chandra et al., 2019; Werry et al., 2019). In addition, structural, functional and metabolic brain imaging are instrumental in evaluating neuronal damage in patients (Johnson K.A. et al., 2012). Yet, most of these methods are not suitable for repeated population screening in the preclinical stages. They are either limited by the use of unsafe ionizing isotopes (radioactivity), high costs, low availability, and/or limited resolution or specificity (Perrin et al., 2009; Ono and Saji, 2011; Johnson J.K. et al., 2012; Johnson K.A. et al., 2012; Koronyo et al., 2012; Mathis et al., 2012; Doraiswamy et al., 2014; James et al., 2015; Kalia and Lang, 2015; Hart et al., 2016; Heurling et al., 2016; Tiepolt et al., 2016; Doustar et al., 2017; Hampel et al., 2018; Baldacci et al., 2020). As it relates to amyloid PET imaging, available tracers and modalities do not allow for detection of early small or soluble forms of Aβ accumulation (Lockhart et al., 2007; Ng et al., 2007; Johnson K.A. et al., 2012)."}

{"project":"2_test","denotations":[{"id":"33041751-17420404-38666051","span":{"begin":309,"end":313},"obj":"17420404"},{"id":"33041751-29213438-38666052","span":{"begin":333,"end":337},"obj":"29213438"},{"id":"33041751-30014145-38666053","span":{"begin":352,"end":356},"obj":"30014145"},{"id":"33041751-30131755-38666054","span":{"begin":373,"end":377},"obj":"30131755"},{"id":"33041751-30203712-38666055","span":{"begin":401,"end":405},"obj":"30203712"},{"id":"33041751-31520513-38666056","span":{"begin":423,"end":427},"obj":"31520513"},{"id":"33041751-31261683-38666057","span":{"begin":443,"end":447},"obj":"31261683"},{"id":"33041751-22474610-38666058","span":{"begin":595,"end":599},"obj":"22474610"},{"id":"33041751-19829371-38666059","span":{"begin":874,"end":878},"obj":"19829371"},{"id":"33041751-21603239-38666060","span":{"begin":894,"end":898},"obj":"21603239"},{"id":"33041751-22562439-38666061","span":{"begin":921,"end":925},"obj":"22562439"},{"id":"33041751-22474610-38666062","span":{"begin":948,"end":952},"obj":"22474610"},{"id":"33041751-22343730-38666063","span":{"begin":970,"end":974},"obj":"22343730"},{"id":"33041751-23026364-38666064","span":{"begin":991,"end":995},"obj":"23026364"},{"id":"33041751-24614494-38666065","span":{"begin":1016,"end":1020},"obj":"24614494"},{"id":"33041751-25806018-38666066","span":{"begin":1036,"end":1040},"obj":"25806018"},{"id":"33041751-25904081-38666067","span":{"begin":1058,"end":1062},"obj":"25904081"},{"id":"33041751-27645291-38666068","span":{"begin":1077,"end":1081},"obj":"27645291"},{"id":"33041751-26440450-38666069","span":{"begin":1100,"end":1104},"obj":"26440450"},{"id":"33041751-27026271-38666070","span":{"begin":1122,"end":1126},"obj":"27026271"},{"id":"33041751-29312125-38666071","span":{"begin":1144,"end":1148},"obj":"29312125"},{"id":"33041751-29562524-38666072","span":{"begin":1165,"end":1169},"obj":"29562524"},{"id":"33041751-32066283-38666073","span":{"begin":1188,"end":1192},"obj":"32066283"},{"id":"33041751-17698496-38666074","span":{"begin":1362,"end":1366},"obj":"17698496"},{"id":"33041751-17401090-38666075","span":{"begin":1379,"end":1383},"obj":"17401090"},{"id":"33041751-22474610-38666076","span":{"begin":1406,"end":1410},"obj":"22474610"}],"text":"Indeed, in recent years there has been tremendous progress in the development of AD diagnostic imaging biomarkers, including FDA-approved brain amyloid imaging via positron emission tomography (PET), as well as tau, surrogate markers of inflammation such as TSPO, and synaptic PET imaging (Rabinovici et al., 2007; Schilling et al., 2016; Chen et al., 2018; Edison et al., 2018; Narayanaswami et al., 2018; Chandra et al., 2019; Werry et al., 2019). In addition, structural, functional and metabolic brain imaging are instrumental in evaluating neuronal damage in patients (Johnson K.A. et al., 2012). Yet, most of these methods are not suitable for repeated population screening in the preclinical stages. They are either limited by the use of unsafe ionizing isotopes (radioactivity), high costs, low availability, and/or limited resolution or specificity (Perrin et al., 2009; Ono and Saji, 2011; Johnson J.K. et al., 2012; Johnson K.A. et al., 2012; Koronyo et al., 2012; Mathis et al., 2012; Doraiswamy et al., 2014; James et al., 2015; Kalia and Lang, 2015; Hart et al., 2016; Heurling et al., 2016; Tiepolt et al., 2016; Doustar et al., 2017; Hampel et al., 2018; Baldacci et al., 2020). As it relates to amyloid PET imaging, available tracers and modalities do not allow for detection of early small or soluble forms of Aβ accumulation (Lockhart et al., 2007; Ng et al., 2007; Johnson K.A. et al., 2012)."}

{"project":"0_colil","denotations":[{"id":"33041751-17420404-816265","span":{"begin":309,"end":313},"obj":"17420404"},{"id":"33041751-29213438-816266","span":{"begin":333,"end":337},"obj":"29213438"},{"id":"33041751-30014145-816267","span":{"begin":352,"end":356},"obj":"30014145"},{"id":"33041751-30131755-816268","span":{"begin":373,"end":377},"obj":"30131755"},{"id":"33041751-30203712-816269","span":{"begin":401,"end":405},"obj":"30203712"},{"id":"33041751-31520513-816270","span":{"begin":423,"end":427},"obj":"31520513"},{"id":"33041751-31261683-816271","span":{"begin":443,"end":447},"obj":"31261683"},{"id":"33041751-22474610-816272","span":{"begin":595,"end":599},"obj":"22474610"},{"id":"33041751-19829371-816273","span":{"begin":874,"end":878},"obj":"19829371"},{"id":"33041751-21603239-816274","span":{"begin":894,"end":898},"obj":"21603239"},{"id":"33041751-22562439-816275","span":{"begin":921,"end":925},"obj":"22562439"},{"id":"33041751-22474610-816276","span":{"begin":948,"end":952},"obj":"22474610"},{"id":"33041751-22343730-816277","span":{"begin":970,"end":974},"obj":"22343730"},{"id":"33041751-23026364-816278","span":{"begin":991,"end":995},"obj":"23026364"},{"id":"33041751-24614494-816279","span":{"begin":1016,"end":1020},"obj":"24614494"},{"id":"33041751-25806018-816280","span":{"begin":1036,"end":1040},"obj":"25806018"},{"id":"33041751-25904081-816281","span":{"begin":1058,"end":1062},"obj":"25904081"},{"id":"33041751-27645291-816282","span":{"begin":1077,"end":1081},"obj":"27645291"},{"id":"33041751-26440450-816283","span":{"begin":1100,"end":1104},"obj":"26440450"},{"id":"33041751-27026271-816284","span":{"begin":1122,"end":1126},"obj":"27026271"},{"id":"33041751-29312125-816285","span":{"begin":1144,"end":1148},"obj":"29312125"},{"id":"33041751-29562524-816286","span":{"begin":1165,"end":1169},"obj":"29562524"},{"id":"33041751-32066283-816287","span":{"begin":1188,"end":1192},"obj":"32066283"},{"id":"33041751-17698496-816288","span":{"begin":1362,"end":1366},"obj":"17698496"},{"id":"33041751-17401090-816289","span":{"begin":1379,"end":1383},"obj":"17401090"},{"id":"33041751-22474610-816290","span":{"begin":1406,"end":1410},"obj":"22474610"}],"text":"Indeed, in recent years there has been tremendous progress in the development of AD diagnostic imaging biomarkers, including FDA-approved brain amyloid imaging via positron emission tomography (PET), as well as tau, surrogate markers of inflammation such as TSPO, and synaptic PET imaging (Rabinovici et al., 2007; Schilling et al., 2016; Chen et al., 2018; Edison et al., 2018; Narayanaswami et al., 2018; Chandra et al., 2019; Werry et al., 2019). In addition, structural, functional and metabolic brain imaging are instrumental in evaluating neuronal damage in patients (Johnson K.A. et al., 2012). Yet, most of these methods are not suitable for repeated population screening in the preclinical stages. They are either limited by the use of unsafe ionizing isotopes (radioactivity), high costs, low availability, and/or limited resolution or specificity (Perrin et al., 2009; Ono and Saji, 2011; Johnson J.K. et al., 2012; Johnson K.A. et al., 2012; Koronyo et al., 2012; Mathis et al., 2012; Doraiswamy et al., 2014; James et al., 2015; Kalia and Lang, 2015; Hart et al., 2016; Heurling et al., 2016; Tiepolt et al., 2016; Doustar et al., 2017; Hampel et al., 2018; Baldacci et al., 2020). As it relates to amyloid PET imaging, available tracers and modalities do not allow for detection of early small or soluble forms of Aβ accumulation (Lockhart et al., 2007; Ng et al., 2007; Johnson K.A. et al., 2012)."}